Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Cardiol Therapeutics Inc. (CRDL) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 6-K Quarterly results
10/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction Results Demonstrate the Active Pharmaceutical Ingredient in Cardiol's Novel CRD-38 Formulation Attenuates Harmful Fat Distribution and Key Markers of Cardiac Inflammation and Remodelling Data Presented at the Heart Failure Society of America Annual Scientific Meeting 2023 Toronto, ON - October 10, 2023 - Cardiol Therapeutics Inc. , a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces positive study results from one of its international collaborating research centers d..."
08/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Condensed Interim Consolidated Financial Statements for the Three and Six Months Ended June 30, 2023",
"Management’ s Discussion and Analysis for the Three and Six Months Ended June 30, 2023",
"Form 52-109F2 Certification of Interim Filings - CEO",
"Form 52-109F2 Certification of Interim Filings - CFO"
08/09/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Toronto, ON - August 9, 2023 - Cardiol Therapeutics Inc. , a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that Cardiol's President and CEO, David Elsley, will present a company overview which will be broadcast live at the Canaccord Genuity 43rd Annual Growth Conference, at the InterContinental Boston Hotel, on August 10, 2023, at 11:00 a.m. EDT. Date: Thursday, August 10, 2023Time: 11:00 a.m. EDTLive Video Webcast Link: www.wsw.com/webcast/canaccord89/crdl/2445355"
08/08/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Oakville, ON - August 8, 2023 - Cardiol Therapeutics Inc. , a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that it received notice on August 7, 2023 from The Nasdaq Stock Market LLC stating the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing on The Nasdaq Capital Market. Accordingly, the Company is now in compliance with all applicable listing standards. "We are pleased to have regained compliance with all applicable listing requirements of the world's premier stock exchange for life sciences companies. Cardiol looks forward to reporting on important milestones associated wi..."
06/29/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Oakville, ON - June 29, 2023 - Cardiol Therapeutics Inc. , a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders held virtually via live audio webcast, on June 28, 2023. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular. Resolutions proposed and approved at the AGM were: The election of the following directors for the ensuing year: David Elsley, Peter Pekos, Dr. Guillermo Torre-Amione, Colin Stott, Michael Willner, Jennifer Chao, Chris Waddick, Teri Loxam. The appointment of BDO Canada LLP as auditors of the Company until the next annual meeting an...",
"Report of Voting Results"
05/18/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Notice of Annual General Meeting of Shareholders",
"Management Information Circular",
"Form of Proxy",
"Notice of Availability of Proxy Materials"
05/15/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Condensed Interim Consolidated Financial Statements for the Three Months Ended March 31, 2023",
"Management’ s Discussion and Analysis for the Three Months Ended March 31, 2023",
"Form 52-109F2 Certification of Interim Filings - CEO",
"Form 52-109F2 Certification of Interim Filings - CFO"
03/29/2023 6-K Quarterly results
03/07/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart Failure Results Demonstrate Cannabidiol Improved Cardiac Function, Reduced its Inflammatory State, and Prevented the Development of Hypertrophy and Fibrosis in Heart Tissue Data Presented at The American College of Cardiology's 72nd Annual Scientific Session Together with the World Congress of Cardiology Oakville, ON - March 7, 2023 - Cardiol Therapeutics Inc. , a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases, announced study results from one of it..."
02/14/2023 SC 13G/A MMCAP International Inc. SPC reports a 7.6% stake in Cardiol Therapeutics Inc.
01/17/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx™ for the Treatment of Recurrent Pericarditis The Cleveland Clinic Recruits First Participant in the Multi-center U.S. Study Oakville, ON - January 17, 2023 - Cardiol Therapeutics Inc. , a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases, announced today that the first patient has been enrolled in the Company-sponsored Phase II open-label pilot study investigating the tolerance, safety, and efficacy of CardiolRx™ in patients with recurrent pericarditis. In addition to standard safety assessments, the..."
11/14/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement"
11/07/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Cardiol Therapeutics Announces Study Results Demonstrating Protective Effects of CardiolRx™ in a Model of Acute Pericarditis Results Demonstrate Significant Reduction in Pericardial Effusion and Thickness and Significant Suppression of Key Inflammatory Markers IL-1β and IL-6 Data Presented at The American Heart Association Scientific Sessions 2022"
10/26/2022 6-K Quarterly results
10/25/2022 6-K Quarterly results
10/03/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx™ Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis Data Presented at The Annual Scientific Meeting of the Heart Failure Society of America September 30 th , 2022"
09/28/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"2265 Upper Middle Road East, Suite 602 Oakville, ON L6H 0G5, Canada Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America Oakville, ON - September 28, 2022 - Cardiol Therapeutics Inc. , a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of cardiovascular diseases , announced today that an abstract submitted by its international research collaborators from Houston Methodist DeBakey Heart & Vascular Center was accepted for poster presentation at The Annual Scientific Meeting of the Heart Failure Society of America to be held in person September 30 th to October 3rd , 2022 in Washington, DC. The poster will be presented ..."
08/10/2022 6-K Quarterly results
08/03/2022 6-K Quarterly results
06/29/2022 6-K Quarterly results
06/27/2022 6-K Quarterly results
06/09/2022 6-K Quarterly results
06/09/2022 SUPPL Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)]:
05/24/2022 6-K Quarterly results
05/19/2022 6-K Quarterly results
05/17/2022 6-K Quarterly results
05/16/2022 6-K Quarterly results
04/20/2022 40-F/A Form 40-F/A - Registration statement [Section 12] or Annual Report [Section 13(a), 15(d)]: [Amend]
03/24/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Update on Operations"
03/24/2022 40-F Form 40-F - Registration statement [Section 12] or Annual Report [Section 13(a), 15(d)]:
03/22/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Cardiol Therapeutics to Participate in Cantor Fitzgerald's Virtual Rare Orphan Disease Summit"
03/15/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"News Release - Cardiol Therapeutics Appoints Jennifer M. Chao to its Board of Directors"
03/01/2022 6-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy